Investigating Preoperative Hematologic Markers for Prediction of Ovarian Cancer Surgical Outcome

Ashrafganjoei, Tahereh;Mohamadianamiri, Mahdiss;Farzaneh, Farah;Hosseini, Maryam Sadat;Arab, Maliheh

  • Published : 2016.04.11


Purpose: The current study aimed at assessing the association between neutrophil-lymphocyte ratio (NLR) and platelet lymphocyte ratio (PLR) for the prognosis of the surgical outcome of epithelial ovarian cancer (EOC). Materials and Methods: EOC patient medical records of surgical operations between January, 2005 and December, 2015 were reviewed and their data of clinicopathological complete blood counts (CBCs) and surgical outcomes were collected. To assess their effects on surgical outcomes, PLR and NLR optimal predictive values were determined and then compared with each other. Results: A statistically significant relation was found between surgical outcomes and NLR and PLR (p<0.001 and p<0.001), for which new cutoff points were gained (PLR: 192,3,293; NLR: 3). The sensitivity and specificity were 0.74 and 0.67, respectively for PLR and 0.74 and 0.58, for NLR. Conclusions: NLR and PLR seem to be useful methods for the prediction of surgical outcomes in patients with EOCs. Increased NLR and PLR proved to be beneficial for poor surgical outcomes. Moreover, PLR increase showed further help in the predicting outcome of EOC suboptimal debulking.


Neutrophil-lymphocyte ratio;platelet-lymphocyte ratio;ovarian masses;optimal debulking;outcome


  1. Asher V, Lee J, Innamaa A, et al (2011). Preoperative platelet lymphocyte ratio as an independent prognostic marker in ovarian cancer. Clin Transl Oncol, 13, 499-503.
  2. Bhatti I, Peacock O, Lloyd G, et al (2010). Preoperative hematologic markers as independent predictors of prognosis in resected pancreatic ductal adenocarcinoma: neutrophil-lymphocyte versus platelet-lymphocyte ratio. Am J Surg, 200, 197-203.
  3. Cho H, Hur HW, Kim SW, et al (2009). Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Immunol Immunother, 58, 15-23.
  4. Clarke-Pearson DL (2009). Clinical practice. Screening for ovarian cancer. N Engl J Med, 361, 170-7.
  5. Fader AN, Rose PG (2007). Role of surgery in ovarian carcinoma. J Clin Oncol, 25, 2873-83.
  6. Fathalla MF (1972). Factors in the causation and incidence of ovarian cancer. Obstet Gynecol Surv, 27, 751-68.
  7. Jemal A, Siegel R, Xu J, et al (2010). Cancer statistics, 2010. CA Cancer J Clin, 60, 277-300.
  8. Kodama S, Tanaka K, Tokunaga A, et al (1997). Multivariate analysis of prognostic factors in patients with ovarian cancer stage I and II. Int J Gynaecol Obstet, 56, 147-53.
  9. Kokcu A, Kurtoglu E, Celik H, et al (2014). May the platelet to lymphocyte ratio be a prognostic factor for epithelial ovarian cancer? Asian Pac J Cancer Prev, 15, 9781-4.
  10. Levin J, Conley CL (1964). Thrombocytosis Associated with Malignant Disease. Arch Intern Med, 114, 497-500.
  11. Li AJ, Madden AC, Cass I, et al (2004). The prognostic significance of thrombocytosis in epithelial ovarian carcinoma. Gynecol Oncol, 92, 211-4.
  12. Markman M, Bundy BN, Alberts DS, et al (2001). Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the gynecologic oncology group, southwestern oncology group, and eastern cooperative oncology group. J Clin Oncol, 19, 1001-7.
  13. Milne K, Alexander C, Webb JR, et al (2012). Absolute lymphocyte count is associated with survival in ovarian cancer independent of tumor-infiltrating lymphocytes. J Transl Med, 10, 33.
  14. Rochet NM, Markovic SN, Porrata LF (2012). The role of complete blood cell count in prognosisa watch this space! Oncol Hematology Review, 8, 76-82.
  15. Siegel RL, Miller KD, Jemal A (2015). Cancer statistics, 2015. CA Cancer J Clin, 65, 5-29.
  16. Smith RA, Ghaneh P, Sutton R, et al (2008). Prognosis of resected ampullary adenocarcinoma by preoperative serum CA19-9 levels and platelet-lymphocyte ratio. J Gastrointest Surg, 12, 1422-8.
  17. Soonthornthum T, Suraseraneewong V, Kengsakol K, et al (2007). Thrombocytosis in advanced epithelial ovarian cancer. J Med Assoc Thai, 90, 1495-500.
  18. Templeton AJ, McNamara MG, Seruga B, et al (2014). Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst, 106, 124.
  19. Thavaramara T, Phaloprakarn C, Tangjitgamol S, et al (2011). Role of neutrophil to lymphocyte ratio as a prognostic indicator for epithelial ovarian cancer. J Med Assoc Thai, 94, 871-7.
  20. Vergote IB, Kaern J, Abeler VM, et al (1993). Analysis of prognostic factors in stage I epithelial ovarian carcinoma: importance of degree of differentiation and deoxyribonucleic acid ploidy in predicting relapse. Am J Obstet Gynecol, 169, 40-52.
  21. Wang DS, Ren C, Qiu MZ, et al (2012). Comparison of the prognostic value of various preoperative inflammation-based factors in patients with stage III gastric cancer. Tumour Biol, 33, 749-56.
  22. Yildirim MA, Seckin KD, Togrul C, et al (2014). Roles of neutrophil/lymphocyte and platelet/lymphocyte ratios in the early diagnosis of malignant ovarian masses. Asian Pac J Cancer Prev, 15, 6881-5.

Cited by

  1. The platelet-to-lymphocyte ratio as a predictor of patient outcomes in ovarian cancer: a meta-analysis vol.20, pp.5, 2017,
  2. The diagnostic efficacy of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in ovarian cancer vol.66, pp.6, 2017,
  3. Role of Intracystic Cytokines and Nitric Oxide in Ovarian Neoplasms vol.86, pp.6, 2017,
  4. Pretreatment neutrophil-to-lymphocyte ratio and its dynamic change during neoadjuvant chemotherapy as poor prognostic factors in advanced ovarian cancer vol.61, pp.2, 2018,